Welcome to BioNTech’s Supplier page

General Corporate Governance

We at BioNTech believe that adhering to the highest Corporate Governance standards positively impacts our performance and we put great importance on building trust with investors, the public and other stakeholders. We are committed to transparency of corporate communication and cooperation between our Management and Supervisory Board aimed at increasing shareholder value over the long term.

Ethical standards in clinical trials

We at BioNTech aim to translate science into survival and work transparently towards our mission. As such, we are committed to the highest industry standards, ensuring that every BioNTech clinical trial complies with international ethical standards, human rights principles and protects the rights, safety, and well-being of all trial participants.

Healthcare transparency

We maintain our core values of integrity, transparency, and responsibility in our engagements with HCPs, HCOs, and Patient Organizations. In line with legislations or industry association codices, BioNTech is committed to making transparent its interactions with such recipients by making the necessary disclosures in several countries across the world through the annual disclosure of these transfers of value.

Whistle blow/speak up

At our company, integrity is a core value. We are committed to fostering a transparent and accountable environment where everyone can feel safe to report concerns. Our Speak Up process ensures that every report is taken seriously, investigated thoroughly, and addressed with fairness. Whether you’ve noticed a potential violation or just need to raise an ethical concern, your voice can make a difference.

As a biotech company engaged in research and commercial manufacturing, BioNTech bears responsibility for how it conducts its business and the impact its activities have on the wider economy, people and the environment.

BioNTech aims to play an active role in climate change mitigation by reducing the emissions under our direct control and reducing indirect emissions in our supply chain. BioNTech’s emission reduction targets have been validated by the Science Based Targets initiative (SBTi).

We are committed to avoid causing or contributing to any adverse impacts on human rights, be it in our own operations or our business relationships with third parties. Our expectations are reflected in the Supplier Code of Conduct.

Taking sustainability and climate-related criteria into consideration in purchasing decisions as well as working closely together with our suppliers is a key element for reaching our climate target.

As part of the supplier selection process, BioNTech requires that any supplier or service provider must follow applicable pharmaceutical and biopharmaceutical manufacturing rules and principles prior to participating in our global supplier network.  

Minimum requirement

We expect our suppliers and service providers to have a Quality Management System (QMS) in place consistent with applicable local and international laws and regulations (e.g., 21CFR211 & 600, EudraLex Volume 4, ISO13485 & 9001).

If the supplier's QMS is not certified, it still must be in place, including the following minimum requirements

• Documented and defined processes
• Training of employees
• Change management/control
• Deviation management
• Corrective action and preventive action management
• Risk management
• GMP grade material (if applicable)
   

Exceptions may be considered on a case-by-case basis with evidence that the supplier or service provider is suitable for pharmaceutical/biopharmaceutical companies. Based on the risk application, more requirements may be necessary. The evidence will be reviewed during the qualification process.